Shares of Zhejiang Anglikang Pharmaceutical Co.,Ltd. (002940.SZ) briefly hit the daily limit up on September 4th, buoyed by news of medical insurance negotiations and the launch of commercial insurance innovative drug catalog consultations, before gains trimmed to close 6.12% higher. However, the stock gave back ground on September 7th, closing down 3.46%. Behind this fleeting bout of capital enthusiasm lies a company mired in the discomfort of strategic transformation.

In the first half of 2026, Anglikang's revenue and net profit both declined by more than 10%. Within its traditional businesses, revenue from active pharmaceutical ingredients (APIs) continued to shrink, while the specialized intermediates segment was nearly halved—becoming the primary drag on performance. Although the formulation business now accounts for over half of total revenue, its growth has notably decelerated, signaling waning momentum. The much-anticipated innovative drug ALK-N001 remains in early clinical stages, with a long road ahead to commercialization. Given that innovative drug R&D is characterized by heavy investment, high risk, and extended timelines, the company is likely to see only expenses, not returns, for a considerable period. While subsidiary Kerui Biotechnology has carved out a niche in plant-derived cholesterol, pharmaceutical-grade applications have yet to scale meaningfully. With legacy growth stalling and future bets far from materializing, whether Anglikang can navigate these pressures remains an open question.

Legacy Segments Weigh Heavily on Results Amid Dual Market Pressure

The first half of 2026 saw Anglikang report a dual decline in both revenue and profit: revenue came in at approximately RMB 627 million, down 13.44% year-over-year; net profit attributable to shareholders was roughly RMB 54.93 million, a 16.68% decrease; and non-GAAP net profit fell 15.77% to RMB 36.81 million.

Revenue structure-wise, Anglikang operates three main segments: chemical APIs, formulations, and specialized intermediates. The formulation business was the only segment posting growth, generating RMB 324 million in revenue for the half, up 3.05% year-over-year, lifting its revenue share to 51.73%. Concurrently, operating costs for this segment dipped 0.37%, and the combined effect boosted gross margin by 1.77 percentage points. However, despite formulations now underpinning the business, growth has clearly slowed compared to the 8.67% recorded in the same period of 2025.

In contrast, the API and specialized intermediates segments suffered steep declines, dragging overall performance. Revenue from APIs—the second-largest revenue source—fell 13.85% year-over-year to approximately RMB 248 million in H1 2026. Looking at a longer timeline, API revenue was roughly RMB 807 million, RMB 747 million, and RMB 576 million in 2023, 2024, and 2025 respectively, with declines attributed to reduced downstream demand for cephalosporin APIs and sharp price drops for alpha-keto acid APIs following centralized procurement of compound alpha-keto acid tablets.

The specialized intermediates segment fared worse, with revenue of approximately RMB 42.51 million in H1 2026, a dramatic 52.83% decline year-over-year. Nevertheless, since operating costs fell even more sharply, the segment's gross margin actually rose countercyclically to 75.61%. For APIs, however, cost reductions lagged revenue declines, pushing the gross margin down further to 20.34%. Given the relatively small scale of specialized intermediates, its improved margin provided limited overall support.

From a market perspective, Anglikang's domestic and international sales revenues decreased by 14.8% and 9.14%, respectively. The gross margin for overseas markets plummeted to 32.38%, down 15.73 percentage points year-over-year, while operating costs for these markets unexpectedly grew 18.4%. Additionally, the company's fundraised project, the "Annual Production of 2.17 Billion Tablets (Capsules, Injections, Sachets) Formulation Manufacturing Base (Phase I)," generated a net profit of RMB 25.997 million in H1, falling short of the promised benefit of RMB 35.451 million. The company attributed this shortfall to price cuts from centralized procurement, reflecting the slowdown in its core operations.

Subsidiary's Plant-Derived Cholesterol Position Faces Growth Verification

In August 2026, a historic turning point emerged in global mRNA tumor therapy: Moderna and Merck jointly announced that their individualized mRNA cancer vaccine met its primary endpoint in a Phase III trial, signaling that the technology may be on the cusp of bridging the commercialization gap from preventive vaccines to solid tumor treatments. As capital chased vaccine developers, attention also turned upstream in the supply chain. As one of the four core lipids in LNP delivery systems, plant-derived cholesterol's strategic value is being reassessed.

Anglikang's controlling subsidiary, Kerui Biotechnology, is positioned in this niche. According to Anglikang, Kerui pioneered the use of phytosterols as starting materials, producing plant-derived cholesterol through bio-fermentation and multi-step chemical synthesis. The resulting cholesterol offers advantages such as abundant raw material sources, lower synthesis costs, and a safer, more environmentally friendly process. Its "Plant-Derived Cholesterol Project" won an excellence award at the 2021 National Disruptive Technology Innovation Competition, and Kerui is China's first company to achieve scaled production of plant-derived cholesterol and plant-derived vitamin D series products.

On the application side, Anglikang's high-purity plant-derived cholesterol products are currently supplied mainly to overseas customers, primarily for high-end cosmetics. In H1 2026, a small portion was pharmaceutical-grade, used in delivery systems for liposomal drugs, mRNA vaccines, and other advanced formulations. Analysts note that from an industry logic standpoint, plant-derived cholesterol is gradually extending toward pharmaceutical excipients, which carry higher certification barriers and added value.

Nevertheless, against the backdrop of the parent company's halved specialized intermediates segment, Kerui itself faced pressure. In H1, Kerui reported revenue of RMB 76.64 million and net profit of RMB 20.77 million. While remaining profitable, both figures declined year-over-year. Potential risks loom as well. Pharmaceutical-grade applications for high-purity plant-derived cholesterol are still nascent, and the downstream mRNA vaccine market is highly susceptible to industry fluctuations. If volume growth disappoints, Kerui's growth prospects could be constrained. Additionally, Anglikang's sharp drop in overseas gross margin may exert pressure on export pricing. Moreover, Anglikang carries goodwill of up to RMB 291 million from the Kerui acquisition; should Kerui's performance weaken, the risk of goodwill impairment could weigh on the parent company's overall financials.

Refinancing Bet on ALK-N001 Faces Long Commercialization Road

Facing pressure on its traditional business base, Anglikang has pinned its transformation hopes on innovative drug R&D. In November 2025, the company unveiled a private placement refinancing plan. After several adjustments, the final scheme involves issuing A-shares to specific investors to raise RMB 1.11 billion, with all net proceeds earmarked for the "Innovative Drug R&D Project," specifically the clinical development of the novel drug ALK-N001. On August 21st, the plan received regulatory approval from the CSRC.

Public information shows ALK-N001 is an innovative tumor microenvironment-activated albumin small-molecule conjugate drug. In February 2024, Anglikang signed a licensing agreement with Prohefa (a partner company) to develop ALK-N001. Under the agreement, Anglikang must pay an upfront fee of RMB 8 million, plus up to RMB 291 million in preclinical development fees and R&D and sales milestone payments. Additionally, during the sales royalty period, Anglikang is required to pay Prohefa royalties of 6% to 12% of sales.

As of the prospectus signing date, ALK-N001's monotherapy indications had entered Phase Ib or Ib/II clinical trials, while combination therapy regimens were in preclinical research with IND application preparations underway. Anglikang believes accelerating innovative drug R&D will enrich its pipeline and create new profit growth points. However, the commercialization timeline is distant: according to clinical trial plans, ALK-N001 monotherapy for various indications is not expected to enter Phase II pivotal trials or Phase III trials until at least 2028, and combination therapy for various indications would enter Phase III no earlier than 2030.

Industry data underscores the challenges. According to an analysis published in China Pharmaceuticals (Vol. 34, Issue 6) by the data team at Yaozhi.com, success rates for chemical innovative drugs at Phase I, Phase II, Phase III clinical trials, and registration application stages are 52.1%, 47.2%, 64.2%, and 80.3%, respectively. Anglikang has cautioned that oncology innovative drugs typically have lower success rates at each stage compared to other drug categories, carrying higher risk and greater uncertainty.

To diversify single-pipeline risk, Anglikang is advancing multiple backup initiatives: improved new drugs ALKA016-1 and NHKC-1 have been submitted for marketing approval. In July 2026, the company invested RMB 50 million in Shengruikang, acquiring a 36.47% equity stake and priority cooperation rights for R&D products in the Greater China region. While these moves spread the uncertainty, they also intensify the overall investment burden.

Short-term sentiment catalysts are unlikely to mask the difficulty of long-term transformation. The key question for the market is how Anglikang will strike a balance between its traditional business and the prolonged incubation period of innovative drugs.